A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study
- 26 June 2016
- journal article
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 54 (9), 1573-1577
- https://doi.org/10.1093/chromsci/bmw106
Abstract
A sensitive and reproducible HPLC method for the determination of linagliptin (LNG) in rat plasma was developed and validated using pindolol (PIN) as the internal standard. Both LNG and PIN were separated on a Zorbax Eclipse XDB C18 column kept at ambient temperature using as mobile phase a combination of 75% methanol: 25% formic acid 0.1% pH 4.1 at a flow rate of 1.0 mL min−1. UV detection was performed at 254 nm. The method was validated in compliance with ICH guidelines and found to be linear in the range of 5–1,000 ng mL−1. The limit of quantification (LOQ) was found to be 5 ng mL−1 based on 100 µL of plasma. The variations for intra- and inter-assay precision were 83%. The assay was successfully applied to an in vivo pharmacokinetic study of LNG in rats that were administered a single oral dose of 10 mg kg−1 LNG. The maximum concentration (Cmax) and the area under the plasma concentration–time curve (AUC0–72) were 927.5 ± 23.9 and 18,285.02 ± 605.76 ng mL−1, respectively.Keywords
This publication has 10 references indexed in Scilit:
- Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes PatientsClinical Therapeutics, 2011
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in HumansDrug Metabolism and Disposition, 2010
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs, 2009
- Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibitionClinical Science, 2009
- Tissue distribution of the novel DPP‐4 inhibitor BI 1356 is dominated by saturable binding to its target in ratsBiopharmaceutics & Drug Disposition, 2009
- Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humansJournal of Pharmacy and Pharmacology, 2009
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 2008
- Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP‐4 inhibitor, in human plasma using liquid–liquid extractionBiomedical Chromatography, 2007
- Global Prevalence of DiabetesDiabetes Care, 2004
- General Derivation of the Equation for Time to Reach a Certain Fraction of Steady StateJournal of Pharmaceutical Sciences, 1982